2025 : Cognivue

Cognivue Named “Top Cognitive Impairment Early Detection Solution 2025” and Featured as October Cover Story in Healthcare Tech Outlook

October 22, 2025

Cognivue has been recognized by Healthcare Tech Outlook as the Top Cognitive Impairment Early Detection Solution for 2025, further solidifying its leadership in advancing timely cognitive assessment. To highlight the achievement, Healthcare Tech Outlook profiled Cognivue in a four-page cover story in its October issue.

Overviewing the Clinical use of the CARM Score in Alzheimer Disease Detection: James Galvin, MD

July 17, 2025

An explanatory video on NeurologyLive features Dr. James Galvin, MD, MPH, Chief Scientific Officer at Cognivue, discussing the clinical use of Cognivue Clarity^® and the new Cognivue Amyloid Risk Measure (CARM)*, and how these tools can inform clinical decisions and guide appropriate next steps in patient staging.

Predicting Amyloid Positivity with CARM: Clinical Insights from James Galvin, MD, MPH

July 7, 2025

A NeurologyLive news article highlights findings from the Bio-Hermes study that led to the development of Cognivue’s new prediction metric, the Cognivue Amyloid Risk Measure (CARM).* In the piece, Dr. James Galvin, MD, MPH, Chief Scientific Officer at Cognivue, shares clinical insights on how CARM, together with the overall Cognivue Clarity^® score, provides meaningful support in predicting amyloid positivity.

New Tool Estimates Amyloid Risk in Early Alzheimer’s

June 16, 2025

News article published on Conexiant about Cognivue's value-add component now integrated into the Cognivue Clarity tool—The Cognivue Amyloid Risk Measure (CARM)*—a cognitive performance–based score that stratifies older adults by predicting likelihood of risk of cerebral amyloid deposition.

Clinical Application and Potential of Cognitive Amyloid Risk Measure: James Galvin, MD, MPH

June 4, 2025

News article and an explanatory video published on NeurologyLive. In it, Dr. James Galvin, MD, MPH, Chief Scientific Officer at Cognivue, gives an informative explanation of the clinical application of Cognivue’s new prediction metric, the Cognivue Amyloid Risk Measure (CARM).*

New Metric Predicts the Likelihood of Amyloid Presence and Leads the Way in Early Alzheimer’s Detection

May 14, 2025

Novel Cognivue CARM Score Feature Now Available on Cognivue Clarity Device; Marks Milestone in Alzheimer’s Early Detection Research
May 14, 2025
Neuroscience technology innovator Cognivue®, today announced a scientific breakthrough with the launch of the Cognivue Amyloid Risk Measure (CARM)*, a novel metric that predicts the likelihood of the presence of amyloid—a key biomarker of Alzheimer’s disease (AD). Now...

New Metric Predicts the Likelihood of Amyloid Presence and Leads the Way in Early Alzheimer’s Detection

May 13, 2025

Archive for year: 2025